Nivolumab plus standard treatment for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or inoperable stomach or esophageal cancer that has spread or cannot be removed.
- Your tumor tested positive for PD-L1 (CPS of 1 or higher) and is microsatellite stable and HER2 negative.
- Your cancer got worse or you had side effects from a first line of treatment that included chemotherapy plus an immunotherapy like nivolumab or pembrolizumab.
- You are at least 18 years old and in fairly good health (able to care for yourself, up and about more than half the day).
- You do not have a serious autoimmune disease, active bleeding, or a history of severe side effects from immunotherapy that caused you to stop treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
This trial tests a lower, less frequent dose of an immunotherapy drug called nivolumab for people with certain advanced cancers. The goal is to see if a reduced dose can still control cancer while causing fewer side effects.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
Hear when a new Advanced Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.